Serum levels of chemerin were shown to be markedly elevated in patients with biopsy-proven non-alcoholic fatty liver disease (NAFLD) compared with healthy controls [10], and elevated hepatic chemerin mRNA expression also was confirmed to be independently associated with liver fibrosis, steatosis, inflammation, and hepatocyte ballooning in human NAFLD [11]. Here, RARRES2 is linked to steatosis.